259 related articles for article (PubMed ID: 26885782)
1. DFD-01, a Novel Medium Potency Betamethasone Dipropionate 0.05% Emollient Spray, Demonstrates Similar Efficacy to Augmented Betamethasone Dipropionate 0.05% Lotion for the Treatment of Moderate Plaque Psoriasis.
Fowler JF; Hebert AA; Sugarman J
J Drugs Dermatol; 2016 Feb; 15(2):154-62. PubMed ID: 26885782
[TBL] [Abstract][Full Text] [Related]
2. Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05.
Stein Gold L; Jackson JM; Knuckles ML; Weiss JS
J Drugs Dermatol; 2016 Mar; 15(3):334-42. PubMed ID: 26954319
[TBL] [Abstract][Full Text] [Related]
3. DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis.
Yamauchi P
Expert Rev Clin Immunol; 2017 Feb; 13(2):85-91. PubMed ID: 27967262
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
Katz HI; Lindholm JS; Weiss JS; Shavin JS; Morman M; Bressinck R; Cornell R; Pariser DM; Pariser RJ; Weng W
Clin Ther; 1995; 17(3):390-401. PubMed ID: 7585843
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
6. Betamethasone dipropionate spray 0.05% alleviates troublesome symptoms of plaque psoriasis.
Stein Gold L; Bagel J; Allenby K; Sidgiddi S
Cutis; 2020 Feb; 105(2):97-102;E1. PubMed ID: 32186532
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
8. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis.
Kircik L; Lebwohl MG; Del Rosso JQ; Bagel J; Stein Gold L; Weiss JS
J Drugs Dermatol; 2013 Dec; 12(12):1404-10. PubMed ID: 24301242
[TBL] [Abstract][Full Text] [Related]
9. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
10. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Eichenfield LF; Ganslandt C; Kurvits M; Schlessinger J
Pediatr Dermatol; 2015; 32(1):28-35. PubMed ID: 25412565
[TBL] [Abstract][Full Text] [Related]
13. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Potency of Betamethasone Dipropionate Spray 0.05%: A Treatment for Adults with Mild-to-moderate Plaque Psoriasis.
Sidgiddi S; Pakunlu RI; Allenby K
J Clin Aesthet Dermatol; 2018 Apr; 11(4):14-22. PubMed ID: 29657667
[No Abstract] [Full Text] [Related]
15. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
[TBL] [Abstract][Full Text] [Related]
16. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.
Buckley C; Hoffmann V; Shapiro J; Saari S; Cambazard F; Milsgaard M
Dermatology; 2008; 217(2):107-13. PubMed ID: 18463448
[TBL] [Abstract][Full Text] [Related]
17. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
van de Kerkhof PC; Hoffmann V; Anstey A; Barnes L; Bolduc C; Reich K; Saari S; Segaert S; Vaillant L
Br J Dermatol; 2009 Jan; 160(1):170-6. PubMed ID: 19067709
[TBL] [Abstract][Full Text] [Related]
18. A controlled clinical trial of a new formulation of betamethasone dipropionate cream in once-daily treatment of psoriasis.
Ellis CN; Katz HI; Rex IH; Shavin JS; Van Scott EJ; VanderPloeg D
Clin Ther; 1989; 11(6):768-74. PubMed ID: 2692821
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
20. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
Pariser D; Bukhalo M; Guenthner S; Kempers S; Shideler S; Gold LS; Tschen E; Berg J; Ferdon MB; Dromgoole S
J Drugs Dermatol; 2017 Mar; 16(3):234-240. PubMed ID: 28301619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
